Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Tafinlar

This page shows the latest Tafinlar news and features for those working in and with pharma, biotech and healthcare.

Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma

Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma

Proactive adjuvant treatment could extend melanoma patient lives. England’s cost effectiveness watchdog NICE has recommended the use of Novartis’Tafinlar (dabrafenib and Mekinst (trametinib) combination in melanoma. ... This is good news for Novartis

Latest news

  • Novartis wins key adjuvant Taf/Mek approval in Europe Novartis wins key adjuvant Taf/Mek approval in Europe

    Novartis’cancer combination Tafinlar and Mekinist has been approved by the EMA for adjuvant treatment of advanced melanoma in order to prevent disease recurrence. ... Tafinlar… particularly given the competition that of course has come up in the class

  • Novartis scores but Roche misses in melanoma trials Novartis scores but Roche misses in melanoma trials

    Novartis scores but Roche misses in melanoma trials. Phase III trial combo success for Tafinlar/Mekinist “unprecedented”. ... A phase III trial of Novartis Tafinlar and Mekinist has confirmed the potential of the pair in the post-surgical treatment

  • Novartis gets lung cancer OK for Tafinlar/Mekinist combo Novartis gets lung cancer OK for Tafinlar/Mekinist combo

    Novartis gets lung cancer OK for Tafinlar/Mekinist combo. It can now be used to treat BRAF V600E-positive NSCLC patients in Europe. ... Novartis acquired Tafinlar and Mekinist as part of its asset-swap deal with GlaxoSmithKline (GSK) in 2015.

  • J&J gets CHMP backing for broader Darzalex use J&J gets CHMP backing for broader Darzalex use

    CHMP round-up. At its meeting last week the CHMP also gave its blessing to the combination of Novartis' Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF-positive non-small cell lung

  • The UK's new Cancer Drugs Fund The UK's new Cancer Drugs Fund

    Gaining the greenlight were Novartis' Zykadia (ceritinib) for lung cancer and melanoma combination Tafinlar (dabrafenib) and Mekinist (trametinib), and Servier's Lonsurf (trifluridine/tipiracil HCl) for bowel cancer.

More from news
Approximately 10 fully matching, plus 36 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2014 Pharma deals during April 2014

    GSK's recently approved MEK inhibitor Mekinist and BRAF inhibitor Tafinlar will position Novartis to become a leader in the potential blockbuster market for metastatic melanoma, neglected by their current portfolio.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Quick links

Infographics

Multimedia